Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years
(Thomson Reuters ONE) -
Novartis International AG /
Novartis seeks leadership with Cosentyx® showing no radiographic progression in
ankylosing spondylitis at 4 years
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* For the first time for any biologic, data show almost 80 percent of
ankylosing spondylitis (AS) patients on Cosentyx(®) have no radiographic
progression of the spine at 4 years[1]
* These new data also confirm sustained improvement in signs and symptoms in
almost 80 percent of patients, with a favorable and consistent safety
profile[1]
* Cosentyx, the only IL-17A inhibitor approved for AS, is a fully human,
highly targeted biologic for first-line use in this chronic inflammatory
disease that can lead to mobility loss[2]
The digital press release with multimedia content can be accessed here:
Basel, November 6, 2017 - Novartis announced today new long-term Cosentyx(®)
(secukinumab) data for patients with ankylosing spondylitis (AS)[1]. This study
is unique as these data show, for the first time with any biologic, that almost
80 percent of AS patients treated with Cosentyx have no radiographic progression
(mSASSS <2) of the spine at 4 years[1]. The new data also confirm sustained
improvement in signs and symptoms in almost 80 percent of patients, while
Cosentyx delivers a favorable and consistent safety profile[1]. The new data
will be presented as a late-breaker during the 2017 American College of
Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual
Meeting in San Diego, United States.
"The key finding of these data is that patients treated with Cosentyx may now
have the opportunity to maintain their mobility for a longer time. This is very
important as ankylosing spondylitis is a crippling condition that can impact
people in their twenties when they still have many decades of their life ahead
of them," said Vas Narasimhan, Global Head, Drug Development and Chief Medical
Officer, Novartis. "For the first time for any biologic, Cosentyx shows that
almost 80 percent of patients had no radiographic progression for as long as 4
years. These data demonstrate the potential of Cosentyx to help patients live
with less pain and retain their mobility for longer".
These new long-term data add to a growing body of evidence demonstrating the
unique position of Cosentyx with lasting efficacy and proven safety across AS,
psoriatic arthritis (PsA) and moderate-to-severe psoriasis[1],[3](-)[6].
Cosentyx is the first and only IL-17A inhibitor approved for AS. Cosentyx is a
highly targeted biologic for first-line use in AS, a chronic inflammatory
disease that can lead to prolonged pain and mobility loss[2].
About Cosentyx and IL-17A
Cosentyx is the first and only fully human IL-17A inhibitor approved to treat
AS, PsA and psoriasis[7]. Cosentyx is a targeted treatment that specifically
inhibits the IL-17A cytokine, which plays a significant role in the pathogenesis
of AS, PsA and plaque psoriasis[7],[8],[9]. Cosentyx is the first IL-17A
inhibitor approved in more than 70 countries for the treatment of active AS and
PsA, which includes the European Union countries and the US. Cosentyx is also
approved for the treatment of PsA and pustular psoriasis in Japan[10].
Cosentyx is also approved in more than 75 countries for the treatment of
moderate-to-severe plaque psoriasis, which includes the European Union
countries, Japan, Switzerland, Australia, the US and Canada. In Europe, Cosentyx
is approved for the first-line systemic treatment of moderate-to-severe plaque
psoriasis in adult patients[7]. In the US, Cosentyx is approved as a treatment
for moderate-to-severe plaque psoriasis in adult patients who are candidates for
systemic therapy or phototherapy (light therapy)[11].
About the MEASURE 1 study
MEASURE 1 is a 2-year, multi-center, randomized, placebo-controlled Phase III
study assessing the efficacy and safety of Cosentyx in patients with active AS.
A total of 290 of 371 patients completed the trial, after which 274 patients
were invited to enter a 3-year extension period[1],[12]. Primary endpoints
assessed superiority of Cosentyx against placebo at Week 16 in the proportion of
patients achieving at least a 20% improvement in the ASAS 20 response
(Assessment of Spondyloarthritis International Society response
criteria)[4],[13]. From Week 16, patients in the placebo arm of the study were
re-randomized to Cosentyx 75 mg or 150 mg based on ASAS 20 response, with non-
responders switched at Week 16, and responders at Week 24[1],[13].
Of the patients participating in the study, almost 80 percent demonstrated no
radiographic progression over 208 weeks of treatment, as indicated by the
modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) X-ray assessment
measure[1]. Importantly, no structural progression of AS in the spine was paired
with sustained results on patient-reported pain measures, with over 75 percent
preserving an ASAS 20 response at 4 years[1]. The safety profile of Cosentyx was
shown to be consistent with that seen in clinical trials across multiple
indications[1],[3](-)[6].
About ankylosing spondylitis (AS)
AS is part of a family of lifelong inflammatory diseases that also includes PsA.
It generally results in serious impairment of movement in the spine and physical
function, which has an impact on quality of life. People in their teens and
twenties, particularly males, are affected most often[14],[15]. Family members
of those with AS are at higher risk[15].
AS is a chronic, inflammatory disease that causes pain and stiffness in the
spine and joints and can lead to a significant loss of mobility if not properly
managed[15],[16]. Many patients with AS respond inadequately to current standard
of care anti-TNF therapies[2]. In severe cases, the spine and joints above the
tailbone can fuse together[16]. Radiography, computed tomography (CT), or
magnetic resonance imaging (MRI) of the spine or sacroiliac joints is needed to
track the progression of AS and the effectiveness of treatment[16].
Improvements in the symptoms of AS are measured by the ASAS response criteria
(ASAS 20). This is defined as an improvement of at least 20 percent, and
absolute improvement of at least 10 units on a 0-100 mm scale in at least three
of the following criteria: improvement in flexibility, night time pain, ability
to perform specific tasks, morning stiffness, and no further deterioration in
the condition. The percentage of patients reaching an ASAS 20 response is an
accepted way of measuring the efficacy of treatments in AS[17].
Disclaimer
This press release contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995. Forward-looking
statements can generally be identified by words such as "potential," "can,"
"will," "plan," "expect," "anticipate," "look forward," "believe," "committed,"
"investigational," "pipeline," "launch," or similar terms, or by express or
implied discussions regarding potential marketing approvals, new indications or
labeling for the investigational or approved products described in this press
release, or regarding potential future revenues from such products. You should
not place undue reliance on these statements. Such forward-looking statements
are based on our current beliefs and expectations regarding future events, and
are subject to significant known and unknown risks and uncertainties. Should one
or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those set
forth in the forward-looking statements. There can be no guarantee that the
investigational or approved products described in this press release will be
submitted or approved for sale or for any additional indications or labeling in
any market, or at any particular time. Nor can there be any guarantee that such
products will be commercially successful in the future. In particular, our
expectations regarding such products could be affected by, among other things,
the uncertainties inherent in research and development, including clinical trial
results and additional analysis of existing clinical data; regulatory actions or
delays or government regulation generally; our ability to obtain or maintain
proprietary intellectual property protection; the particular prescribing
preferences of physicians and patients; global trends toward health care cost
containment, including government, payor and general public pricing and
reimbursement pressures; general economic and industry conditions, including the
effects of the persistently weak economic and financial environment in many
countries; safety, quality or manufacturing issues, and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2016, the Group achieved
net sales of USD 48.5 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
121,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
References
[1] Braun J et al. Secukinumab demonstrates low radiographic progression and
sustained efficacy through 4 years in patients with active ankylosing
spondylitis. Late breaking abstract presented at the 2017 ACR/ARHP Annual
Meeting, San Diego, USA. 7(th) November 2017.
[2] Dougados M et al. Spondyloarthritis. Lancet. 2011;377:2127-37.
[3] Bissonnette R et al. Secukinumab demonstrates high sustained efficacy and
a favorable safety profile through 5 years of treatment in moderate to severe
psoriasis. Presented as eposter P2223 at 26th EADV Congress 2017. 13th September
2017.
[4] Baeten D et al. Secukinumab, interleukin-17A inhibition in ankylosing
spondylitis. N Engl J Med. 2015; 373:2534-48.
[5] McInnes IB et al. Secukinumab, a human anti-interleukin-17A monoclonal
antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386(9999):1137-1146.
[6] Mease PJ et al. Secukinumab Provides Sustained Improvements in the Signs
and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety
Results from a Phase 3 Trial. AnnRheum Dis. 2017;76:952-953.
[7] Cosentyx Summary of Product Characteristics. Novartis Europharm Limited.
Available at:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/0037
29/human_med_001832.jsp&mid=WC0b01ac058001d124. Last accessed October 2017.
[8] Nestle FO et al. Mechanisms of disease psoriasis. N Eng J Med.
2009;361:496-509.
[9] Girolomoni G et al. Psoriasis: rationale for targeting interleukin-17. Br
J Dermatol. 2012;167:717-24.
[10] Pharmaceuticals and Medical Devices Agency. Review Report. Available at:
http://www.pmda.go.jp/files/000216877.pdf. Last accessed October 2017.
[11] Cosentyx (secukinumab) [prescribing information]. East Hanover, NJ:
Novartis Pharmaceuticals Corp, 2016.
[12] Baraliakos X et al. Secukinumab provides sustained improvements in the
signs and symptoms of active ankylosing spondylitis: 3-year results from a phase
3 extension trial (MEASURE 1). Presented at the Annual European Congress of
Rheumatology (EULAR 2017). 15(th) June 2017.
[13] Braun J et al. Effect of secukinumab on clinical and radiographic outcomes
in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE
1 study. Ann Rheum Dis. 2016;doi: 10.1136/annrheumdis-2016-209730.
[14] Dean LE, et al. Global prevalence of ankylosing spondylitis. Rheumatology
(Oxford). 2014; 53(4):650-7.
[15] Reveille JD. American College of Rheumatology. Spondyloarthritis.
Available at: http://www.rheumatology.org/IAm- A/Patient-Caregiver/Diseases-
Conditions/Spondyloarthritis. Accessed October 2017.
[16] Sieper J et al. Ankylosing spondylitis: an overview. Ann Rheum Dis
2002; 61 (Suppl III):iii8-iii18.
[17] Committee for Medicinal Products for Human Use. Guideline on clinical
investigation of medicinal products for the Treatment of ankylosing spondylitis.
London: European Medicines Agency; 2009. Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/0
9/WC500003424.pdf Last accessed October 2017.
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Friedrich von Heyl
Novartis Global Media Relations Novartis Global Pharma Communications
+41 61 324 7999 (direct) +41 61 324 8984 (direct)
+41 79 593 4202 (mobile) +41 79 749 0286 (mobile)
eric.althoff(at)novartis.com friedrich.vonheyl(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2147245/823485.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 06.11.2017 - 07:15 Uhr
Sprache: Deutsch
News-ID 566663
Anzahl Zeichen: 16185
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 364 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
